LEVOCARNITINE

Post-LOE

levocarnitine

Hikma

ANDAORALSOLUTION

Approved

Oct 2007

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

LEVOCARNITINE (levocarnitine) by Hikma is clinical pharmacology levocarnitine is a naturally occurring substance required in mammalian energy metabolism. Approved for the treatment of primary systemic carnitine deficiency. First approved in 2007.

Drug data last refreshed 19h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Levocarnitine is a naturally occurring substance required in mammalian energy metabolism. It has been shown to facilitate long-chain fatty acid entry into cellular mitochondria, thereby delivering substrate for oxidation and subsequent energy production. Fatty acids are…

Worked on LEVOCARNITINE at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

LEVOCARNITINE

Mechanism of Action

Indications (1)